Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapeutics II > Pulmonary Arterial HTN > Flashcards

Pulmonary Arterial HTN Flashcards

1
Q

Normal hear anatomy

A
  1. superior vena cava
  2. inferior vena cava
  3. right atrium
  4. Tricuspid valve
  5. Right ventricle
  6. Pulmonary valve
  7. Pulmonary arteries

oxygen rich

  1. Pulmonary veins
  2. Left atrium
  3. Mitral valve
  4. Left ventricle
  5. Aortic valve
  6. Aorta
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pulmonary Arterial HTN (PAH) patho

A

-pulmonary arterioles narrow
-RV dilates
-pulmonary edema and damage
-thrombo and/or plexiform lesion formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pulmonary HTN (PH)

A

-higher than normal BP in arteries going from heart to lung
-mean artery pressure (MPAP) > 20mmHg at rest
-more common than PAH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pulmonary Arterial HTN (PAH)

A

-progressive
-endothelial dysfunction
-elevated pulmonary arterial pressure and pulmonary vascular resistance
-rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PH classifications

A
  1. PAH
  2. Left Heart Disease
  3. Lung Disease
  4. Chronic Thromboembolic PH
  5. PH from unclear mechanisms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Group 1: PAH causes

A

-unknown causes
-genetic/drug/toxin
-CHD, HIV, connective tissue disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Group 1: PAH tx

A

-meds fro PAH
-CCB in responders
-lung transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PAH (Grp1) Epidemiology

A

-rare
-2-7mil a year
-mean age 50 +/- 14
-underrecognized (1.1 years to heart catheter)
-1/5 asx > 2 years to diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PAH prognosis

A

-poor but improving
-15% mortality in 1 year
-median survival 6 years
-negative predictors: advanced functional class, poor exercise capacity, hight right atrial pressure, right ventricular dysfinction, low CO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Early PAH sx

A

-nonspecific = large differential diagnosis
-dizziness
-SOB
-palpitations
-fatigue
-edema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Late sx of PAH

A

-signs of right-sided HF
-syncope
-jugular venous distension
-SOB
-chest pain
-hepatomegaly
-swollen abdomen
-low BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnosis

A

-echocardiogram: eval RV function, PAP, and PVR
-Right Heart Catheterization: confirms dx, estimates severity, assess response to pulmonary vasodilators before starting therapy (AVT)
-exercise testing: distance walked in 6 min
-biomarkers: BNP and NTproBNP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diagnositic imaging/procedure

A

-slide12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PAH labs

A

-mPAP > 20mmHg (mean pulmonary artery pressure)
-PAWP =/< 15mmHg (pulmonary artery wedge pressure)
-PVR > 2 wood units (pulm vasc resistance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pulmonary arterial wedge pressure (PAWP)

A

-estimates left atrial pressure
-normal 4-12
-PAH: 15mmHg
-elevated numbers = LV failure or mitral stenosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pulmonary vascular resistance (PVR)

A

-calc using mPAP and PAWP
-PAH: >2 wood units

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

WHO functional classifications

A

I: no limits
II: slight limit
III: marked limit
IV: inability to be active wo sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Risk

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Pharma options for PAH

A

-CCB (if vasoreactive +)
-PDE-5 inhibitors
-sGC
-ERAs
-Prostacyclins
-Direct pulmonary vasodilator (inpatient only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Vasoreactivity test

A

-done in cath lab during initial hemodynamic eval
-acute response to pulmonary-specific vasodilators predicts response to CCBs
-use inhaled NO or epoprostenol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Positive Vasoreactivity test

A

=drop in mPAP>10 w PAP less than 40 w stable-improved CO
-can initiate CCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

CCB for PAH

A

-inc in calcium causes vasoconstriction and stimulates proliferation, migration, vascular remodeling
-only 5% of pt respond
-continually assess w vasoreactive test
-goal: improve to FCI or II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

which CCBs to use

A

-nifedipine 120-240mg
-diltiazem 240-720mg
-amlodipine 20mg

-NO verapamil bc negative inotropic events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

PAH tx that effects NO pathway

A

-PDE-5 inhibitors
-sGCs

26
Q

PDE-5 inhibitors mech

A

-dec conversion of cGMP to GMP
-inc levels of cGMP = vasodilation
-can be monotherapy but often combo

27
Q

PDE-5 inhibitor drugs for PAH

A

-sildenafil 20mg
-tadalafil 40mg
-improved 6MWD, functional capacity

-hearing/vision loss
-hypotension
-AVOID CYP3a4 subdtrates

28
Q

Soluble Guanylate Cyclase Stimulator (sGC)

A

-riociguat
-may use as ALT to PDE-5 (do NOT combo = hypotension)
-antiproliferating and antiremodeling
-improves exercise capacity, FC, and time to worsening

29
Q

Endothelin receptor antagonist drugs

A

-Bosentan (mixed)
-Ambrisentan (ETA)
-Macitentan (ETA and ETB)

-selectivity purpose unclear

30
Q

ETA receptors

A

-located on pulmonary smooth muscle walls
-promotes vasoconstriction, proliferation, and inflammation
-targeted by bosentan and ambrisentan and macitentan

31
Q

ETB receptors on endothelium

A

-vasodilation
-stimulate NO and prostacyclin production

32
Q

ETB receptors on muscle cells of vascular walls

A

-vasoconstriction
-cell proliferation
-upregulated expression in vasoconstriction

33
Q

ERAs improve

A

-exercise capacity (6MWD)
-FC
-hemodynamic parameters
-time to clinical worsening
-WHO FC
-improvement seen around 8-10 weeks

34
Q

ERA STUFF

A

-

35
Q
A
36
Q
A
37
Q
A
38
Q
A
39
Q
A
40
Q
A
41
Q
A
42
Q

Prostacyclin pathway

A

-prostacyclin stimulates cAMP to increase pulmonary vasodilation
-parenteral prostacyclins are standard for severe PH w RV failure

43
Q

Prostacylin drugs

A

-epoprostenol (IV)
-Treprostinil (IV, inhaled, PO, SubQ)
-selexipag (prostacyclin IP receptor agonist)

44
Q

Prostacyclin overview

A

-oral for low risk class III
-IV firstlin if class IV or rapidly progressing class III
-improve sx, 6, hemodynamics (mortality in epoprostenol))
-can combo with ERA and PDE-5 or riociguat
-NO oral, inhaled and parenteral concurrently

45
Q

Prostacyclin mech

A

-induce vasodilation in all vascular beds
-inhibits platelet aggregation
-cytoprotective
-antiproliferative effect

46
Q

Prostacyclin ADRs

A

-thrombocytopenia (worse in epoprostenol)
-hypotension
-HA, pain, diarrhea

47
Q

Oral prostacyclins

A

-option for pt who cannot use parenteral therapy
-Treprostinil
-Selexipag

48
Q

Inhaled prostacyclins

A

-option for pt who cannot use parenteral therapy
-Treprostinil (Tyvaso)

49
Q

Tyvaso

A

-charged/plugged in
-assemble device qd
-2-3 min tx throughout the way

50
Q

Tyvaso DPI

A

-no charging needed
-simpler assembly
-single inhalation per cartridge

51
Q
A
52
Q

Treprostinil IV/SubQ (REmodulin)

A

-4 hour halflife
-always dose by weight at beginning
-start 1-3ng/kg/min and titrate q8-12h to 10-20ng/kg/min then weekly at home by 2ng/kg/min increments up to goal (~50-80)

53
Q

Treprostinil IV vs SQ

A

-IV if SQ not tolerated
-SQ avoids risk of central lines (infection)
-SQ more site reactions (tx w antihistamines)
-SQ undiluted, IV needs diluent
-SQ pumps small e and more portable

54
Q

Prostacyclin: Epoprostenol IV

A

-Flolan (needs to be on ice)
-Veletri (stable 48h)
-3-5min t1/2
-must ALWAYS have backup cassette prepeared
-abrupt d/c might precipitate PH crisis
-DO NOT COADMIN W ANY OTHER FLUIDS

55
Q

Prostacyclin med errors

A

-flushing of line
-calc error
-programming error
-pump turned off
-inappropriate change in weight

56
Q

AMBITION trial

A

-ERA + PDE5i as initial therapy for pt WHO class II or III

57
Q

PAH treatment guidelines

A

-PDE5i + ERA (low/mid risk)
-add iv/sc PCA (high risk)
-PDE5i OR ERA (comorbidities)
-add PRA or switch PDE5i to sGC if above is not working

58
Q

PAH CV comorbidities

A

-obesity
-HTN
-DM
-CAD
-lung disease

59
Q

Sotatercept-csrk (Winrevair)

A

-new
-activin inhibitor
-mAb trap for TGF-B
-restores balance between growth promoting and growth inhibiting pathways
-SQq24days (reconstitiute)
-avg peak onset 7 days w t1/2 24 days

60
Q

Sotatercept-csrk (Winrevair) use

A

-adults w PAH to:
-inc exercise capacity
-inc functional class
-dec risk of clinical worsening events

61
Q

Sotatercept-csrk adverse effects

A

-erthrocytosis
-thrombocytopenia
-hemorrhage
-HA, epistaxis, inj site
-embryo-fetal harm
-impaired fertility
-AVOID in breastfeeding

62
Q

PAH considerations

A

-maybe diuretics, O2, CV drugs
-IV iron
-flu and pneumonia vax

63
Q

PAH tx in pregnancy

A

-use CCBs, PDE5, and prostacyclins
-AVOID ERAs, riociguat, selexipag
-us contraception

64
Q

PAH and traveling

A

-supp O2 at sea level or high alt
-travel w info abt disease and meds

65
Q

Disease progression guidelines

A

-add ERA
-add inhaled prostacyclin
-consider lung transplant

Therapeutics II (55 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions